KEAP1 and non-small cell lung carcinoma: Similarly, KEAP1 mutations were found to be associated with poorer clinical outcomes in LUAD patients receiving pembrolizumab in combination with carboplatin and pemetrexed, the standard first-line treatment options for driver-negative non-squamous NSCLC [77].